Limited Offer
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Cancer Immunotherapy
- 1st Edition, Volume 209 - November 1, 2024
- Editor: David B. Teplow
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 3 5 3 4 - 4
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 3 5 3 5 - 1
Cancer Immunotherapy, Volume 209 covers the progress that has been made in cancer immunotherapy. This volume surveys exciting developments in the field while also highli… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteCancer Immunotherapy, Volume 209 covers the progress that has been made in cancer immunotherapy. This volume surveys exciting developments in the field while also highlighting its promise and problems. Chapters in this release include The Promise, Progress, and Challenges of In Situ Immunization Agents in Cancer Immunotherapy, Breakthroughs in Synthetic Controlling Strategies for Precision in CAR-T Therapy, Non-coding RNAs in cancer immunotherapy: a solution to overcome immune resistance?, Rational Design of adjuvants boosts cancer vaccines, Emerging Drug delivery systems to alter Tumor immunosuppressive microenvironment: overcoming the challenges in immunotherapy for Glioblastoma.
Other chapters cover Magnetic Nanoparticles: An Emerging Nanomedicine for Cancer Immunotherapy and Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment.
Other chapters cover Magnetic Nanoparticles: An Emerging Nanomedicine for Cancer Immunotherapy and Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment.
1. The Promise, Progress, and Challenges of In Situ Immunization Agents in Cancer Immunotherapy
Matt Giacalone
2. TBA
Tiziana Vavalà
3. Breakthroughs in Synthetic Controlling Strategies for Precision in CAR-T Therapy
Rio Sugimura and Logan Tang
4. Non-coding RNAs in cancer immunotherapy: a solution to overcome immune resistance?
Moein Ala, Fatemeh Afra, Seyed Parsa Eftekhar and Amir Salehi Farid
5. Rational Design of adjuvants boosts cancer vaccines
Xia Li, Mitsuhiro Ebara, Naoto Shirahata, Tomohiko Yamazaki and Nobutaka Hanagata
6. Emerging Drug delivery systems to alter Tumor immunosuppressive microenvironment: overcoming the challenges in immunotherapy for Glioblastoma
Khushwant S. Yadav
7. MAGNETIC NANOPARTICLES: AN EMERGING NANOMEDICINE FOR CANCER IMMUNOTHERAPY
Phoomipat Jungcharoen, Jutatip Panaampon, Thanit Imemkamon and Charupong Saengboonmee
8. TBA
Mi Liu
9. TBA
Sarbajit Mukherjee
10. TBA
Gerardo Cazzato III
11. Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment
Eric Jou
Matt Giacalone
2. TBA
Tiziana Vavalà
3. Breakthroughs in Synthetic Controlling Strategies for Precision in CAR-T Therapy
Rio Sugimura and Logan Tang
4. Non-coding RNAs in cancer immunotherapy: a solution to overcome immune resistance?
Moein Ala, Fatemeh Afra, Seyed Parsa Eftekhar and Amir Salehi Farid
5. Rational Design of adjuvants boosts cancer vaccines
Xia Li, Mitsuhiro Ebara, Naoto Shirahata, Tomohiko Yamazaki and Nobutaka Hanagata
6. Emerging Drug delivery systems to alter Tumor immunosuppressive microenvironment: overcoming the challenges in immunotherapy for Glioblastoma
Khushwant S. Yadav
7. MAGNETIC NANOPARTICLES: AN EMERGING NANOMEDICINE FOR CANCER IMMUNOTHERAPY
Phoomipat Jungcharoen, Jutatip Panaampon, Thanit Imemkamon and Charupong Saengboonmee
8. TBA
Mi Liu
9. TBA
Sarbajit Mukherjee
10. TBA
Gerardo Cazzato III
11. Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment
Eric Jou
- No. of pages: 300
- Language: English
- Edition: 1
- Volume: 209
- Published: November 1, 2024
- Imprint: Academic Press
- Hardback ISBN: 9780443235344
- eBook ISBN: 9780443235351
DT
David B. Teplow
David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid β-protein (Alzheimer's disease) and α-synuclein (Parkinson’s disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Co-Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.
Affiliations and expertise
Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA